We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)
We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Updated: 12/31/1969
A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Updated: 12/31/1969
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Updated: 12/31/1969
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Updated: 12/31/1969
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Updated: 12/31/1969
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome
Updated: 12/31/1969
A Pilot, Randomized Trial of Mindfulness-based Irritable Bowel Syndrome Eating Awareness Training as Compared to the Standard Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide and Polyol Diet in Patients With IBS
Status: Enrolling
Updated: 12/31/1969
Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome
Updated: 12/31/1969
A Pilot, Randomized Trial of Mindfulness-based Irritable Bowel Syndrome Eating Awareness Training as Compared to the Standard Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide and Polyol Diet in Patients With IBS
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Updated: 12/31/1969
A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials